Related to It's Time to Break Your Silence about Workplace Discrimination

• Novartis to License Phase II Anticlotting Therapy from Portola for $75M
  
• Novartis to Kick Off R&D Alliance with Epistem with $4M
  
• Proteon Secures $38M Financing and Option Agreement with Novartis Related to Lead Candidate
  
• Novartis Licenses MDRNA's siRNA Delivery Technology for $7.25M
  
• Novartis Seeks to Increase Stake in Novartis India
  
• Novartis and Schering-Plough Divide Spoils of Respiratory Therapies Collaboration
  
• Novartis to Buy EBEWE Pharma’s Generics Business for $1.2B
  
• Preliminary Phase III Data Is Positive for Novartis’ COPD Drug
  
• Novartis Offers 28% More for Increased Control over India Operations
  
• Novartis' Osteoporosis Drug Gets FDA Okay for Preventing Postmenopausal Osteoporosis
  
• Novartis Vaccines Institute Gets Roughly $7M to Develop Bivalent Typhoid Vaccine
  
• Novartis Gets FDA Okay for Drug to Treat Rare Inflammatory Disorder
  
• EU Sanctions Novartis Drug for Steroid-Induced Osteoporosis
  
• Vectura and Sosei Receive $7.5M Each with Start of Phase III COPD Trial by Novartis
  
• Novartis and OneWorld Health Join Forces against Secretory Diarrhea
  
• Alnylam and Novartis Take RNAi Therapeutics Collaboration into Fifth Year
  
• FDA Clears Novartis Medication as Initial Therapy for Blood Pressure
  
• Novartis Invests in Avila’s Protein-Silencing Covalent Drug Development Efforts
  
• Novartis Starts Shipment of Seasonal Flu Vaccine to the U.S.
  
• Novartis’ Afinitor Receives EU Sanction for Advanced RCC After Failed Anti-VEGF Therapy